S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Is Gold Really Boring? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Is Gold Really Boring? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Is Gold Really Boring? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Is Gold Really Boring? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Stock Forecast, Price & News

$52.49
+0.40 (+0.77%)
(As of 10/2/2023 ET)
Compare
Today's Range
$51.67
$52.75
50-Day Range
$52.09
$61.96
52-Week Range
$42.01
$67.05
Volume
766,258 shs
Average Volume
600,509 shs
Market Capitalization
$5.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.78

Intra-Cellular Therapies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
50.1% Upside
$78.78 Price Target
Short Interest
Healthy
2.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
1.29mentions of Intra-Cellular Therapies in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$6.36 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.08) to ($0.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

Medical Sector

95th out of 975 stocks

Pharmaceutical Preparations Industry

28th out of 448 stocks


ITCI stock logo

About Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

ITCI Price History

ITCI Stock News Headlines

The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Intra-Cellular Therapies Q2 2023 Earnings Preview
ITCI Jul 2023 65.000 call
Analyst Expectations for Intra-Cellular Therapies's Future
See More Headlines
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Company Calendar

Last Earnings
8/03/2023
Today
10/03/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITCI
Employees
561
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$78.78
High Stock Price Forecast
$98.00
Low Stock Price Forecast
$62.00
Forecasted Upside/Downside
+50.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-256,260,000.00
Pretax Margin
-50.36%

Debt

Sales & Book Value

Annual Sales
$364.16 million
Book Value
$6.93 per share

Miscellaneous

Free Float
92,665,000
Market Cap
$5.04 billion
Optionable
Optionable
Beta
1.10
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Sharon Mates Ph.D. (Age 70)
    Co-Founder, Chairman, CEO & Pres
    Comp: $2.23M
  • Mr. Lawrence J. Hineline CPA (Age 67)
    CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec.
    Comp: $820.53k
  • Mr. Michael I. Halstead J.D. (Age 50)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $983.65k
  • Dr. Suresh K. Durgam M.D. (Age 54)
    Exec. VP & Chief Medical Officer
    Comp: $961.84k
  • Mr. Mark NeumannMr. Mark Neumann (Age 60)
    EVP & Chief Commercial Officer
    Comp: $998.36k
  • Dr. Robert E. Davis Ph.D. (Age 72)
    Sr. VP & Chief Scientific Officer
  • Mr. Juan Fernando Sanchez (Age 52)
    VP of Corp. Communications & Investor Relations
  • Ms. Karen Patruno Sheehy Esq. (Age 61)
    Sr. VP & Chief Compliance Officer
  • Dr. Michael Olchaskey
    Sr. VP & Head of Regulatory Affairs
  • Mr. John A. Bardi
    Sr. VP of Market Access, Policy & Gov. Affairs













ITCI Stock - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings
or view top-rated stocks.

What is Intra-Cellular Therapies' stock price forecast for 2023?

8 Wall Street analysts have issued 1-year price objectives for Intra-Cellular Therapies' stock. Their ITCI share price forecasts range from $62.00 to $98.00. On average, they expect the company's stock price to reach $78.78 in the next twelve months. This suggests a possible upside of 50.1% from the stock's current price.
View analysts price targets for ITCI
or view top-rated stocks among Wall Street analysts.

How have ITCI shares performed in 2023?

Intra-Cellular Therapies' stock was trading at $52.92 on January 1st, 2023. Since then, ITCI stock has decreased by 0.8% and is now trading at $52.49.
View the best growth stocks for 2023 here
.

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a decline in short interest in September. As of September 15th, there was short interest totaling 2,230,000 shares, a decline of 12.5% from the August 31st total of 2,550,000 shares. Based on an average trading volume of 639,800 shares, the days-to-cover ratio is currently 3.5 days.
View Intra-Cellular Therapies' Short Interest
.

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ITCI earnings forecast
.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.17. The biopharmaceutical company earned $110.80 million during the quarter, compared to the consensus estimate of $106.45 million. Intra-Cellular Therapies had a negative net margin of 50.40% and a negative trailing twelve-month return on equity of 28.63%. The business's revenue was up 99.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.92) earnings per share.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $52.49.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.04 billion and generates $364.16 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

The company employs 561 workers across the globe.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.

This page (NASDAQ:ITCI) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -